Experimental Pill AD109 Shows Promise in Reducing Sleep Apnea Symptoms
AD109, an experimental pill developed by Apnimed, has shown promising results in reducing symptoms of sleep apnea by 44% in a Phase 3 clinical trial. The drug, a combination of aroxybutynin and atomoxetine, aims to replace CPAP machines by improving airway function during sleep. The trial involved participants with obstructive sleep apnea who could not use CPAP, and results indicated significant improvements in their apnea-hypopnea index. Despite the promising data, some sleep doctors remain skeptical about the drug's effectiveness, particularly for severe cases of sleep apnea. 
